Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition

Qiong Yang1,2 · Florian Puhm1,2 · Michael Freissmuth1,2 · Christian Nanoff1,2

Received: 6 March 2017 / Accepted: 11 July 2017 / Published online: 4 August 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Purpose Small-molecule inhibitors of heat-shock protein 90 (HSP90) have been under development as chemotherapeutic agents. The adverse events reported from early clinical trials included hyponatremia. Given the limited number of patients enrolled, the number of hyponatremia incidents was remarkable and repeatedly, the event was judged as severe. Inappropriate V2 vasopressin receptor stimulation is an established cause of hyponatremia. We explored the hypothesis that HSP90 inhibition produces hypersensitivity to vasopressin by upregulating V2-receptors.

Methods Experiments were carried out in cell culture using HEK293 cells with heterologous expression of the human V2-receptor and HELA cells with an endogenous V2-receptor complement. We tested the effect of HSP90 inhibition by three structurally unrelated compounds (alvespimycin, luminespib, radicicol) and asserted its specificity in cells depleted of cytosolic HSP90 (by RNA interference). Assays encompassed surface V2-receptor density and vasopressin-stimulated formation of cyclic AMP (cAMP).

Results The results demonstrate a twofold increase in cell-surface receptor density following pre-incubation with each of the HSP90 inhibitors. The effect had a concentration-dependence consistent with the individual potencies to inhibit HSP90. Similarly, depletion of cytosolic HSP90 increased surface-receptor density and at the same time, reduced the inhibitor effect. Upregulated V2-receptors were fully functional; hence, in culture treated with an HSP90 inhibitor, addition of vasopressin resulted in higher levels of cAMP than in controls.

Conclusion Since formation of cAMP is the first signalling step in raising water permeability of the collecting duct epithelia, we suggest that V2-receptor upregulation generates hypersensitivity to vasopressin linking HSP90 inhibition to the development of hyponatremia.

Keywords Hyponatremia · HSP90 inhibitor · V2 vasopressin receptor · Upregulation · HELA cells

Introduction

The original finding that preceded the introduction of HSP90 inhibitors as chemotherapeutic agents was the observation that benzoquinone ansamycins restored the phenotype of cells transformed with oncogenic tyrosine kinases [1]. The predominant cellular binding site of the benzoquinone ansamycins such as geldanamycin is the ATPase domain of HSP90, the occupancy of which impairs the activity of protein kinases, a major class of binding partners of cytosolic HSP90 (reviewed in [2]).

Although targeting HSP90 has shown promise in preclinical tumour models, the inhibitors unfortunately were of limited efficacy in the clinic, presumably because of rapidly emerging resistance. A strategy has been to overcome resistance by introducing chemically unrelated inhibitory compounds. From recent phase I/II clinical trials that enrolled patients with various kinds of cancer, a good number reported on hyponatremia as adverse event; these reports are summarized in Table 1. With about 380
patients treated over short time, the event count was 60. The severity grades suggest that in some instances hyponatremia may have been dose-limiting. Given the structural diversity of the compounds employed (half of which were not benzoquinone ansamycins) an off-target effect was unlikely relevant. Therefore, our conjecture was that HSP90 inhibition is causally linked to the aetiology of hyponatremia.

While it is largely unknown how HSP90 selects its clients, due to its physical abundance it is certainly poised for engaging cellular proteins as binding partners. The cytosolic isoforms (HSP90α/HSP90AA1 and HSP90β/HSP90AA2) make up for a significant fraction (>1%) of the mass of cytoplasmic proteins. It is therefore not surprising that experimental evidence has revealed an increasing number of cellular functions HSP90 impinges on. A few studies have addressed the effect of HSP90 on signaling-competent G-protein-coupled receptors and reported an increase with a decline in HSP90 activity [15, 16].

The V2 vasopressin receptor is a Gs-coupled receptor with a singular action in kidney physiology. Activation by its agonist restrains the excretion of water. Excessive V2-receptor activation is the cause of hyponatremia as in the case of inappropriate vasopressin secretion (SIADH) and may herald water intoxication. Therefore, we tested the assumption that treatment with HSP90 inhibitors sensitizes cells to the V2-receptor-mediated effect of vasopressin. In addition to the prototypical HSP90-inhibitor DMAG (alvespimycin), we used two chemically unrelated compounds (radicicol and luminespib). DMAG and luminespib had been used in clinical trials where hyponatremia occurred as an adverse event (Table 1). Our experimental evidence demonstrates that HSP90 inhibition increased V2-receptor levels and enhanced vasopressin signalling consistent with the hypothesis that HSP90 inhibition predisposes to hyponatremia by upregulating the V2-receptor.

### Materials and methods

A polyclonal antibody that recognizes both HSP90α and β isoforms (HSP90AA1 and AB1) and a monoclonal directed against GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were from Cell Signaling Technology. The Alexa Fluor 488-conjugated F(ab’2)2 fragment of goat anti-mouse IgG was from LifeTechnology.

The radiotracers [3H]adenine and [3H]arginine-vasopressin were purchased from PerkinElmer (Waltham, Massachusetts). SR121463 (SR) was kindly made available by Dr. Claudine Serradeil (Sanofi-Aventis, Toulouse, France). Luminespib (NVP-AUY922) was from Selleckchem (Munich, Germany).

The following reagents were from Sigma-Aldrich: M2-monoclonal anti-FLAG antibody, analytical grade 17-dimethylaminooethylamino-17-demethoxygeldanamycin (DMAG), radicicol, forskolin, arginine–vasopressin (AVP) and primer oligonucleotides. Restriction enzymes were from Roche-Diagnostics (Mannheim, Germany), Pfu-DNA-Polymerase from Agilent (Santa Clara, California), chromatography resin for DNA purification from Macherey-Nagel (Düren, Germany). All other reagents were of the highest quality grade available.

Stock solutions of SR121463, DMAG and radicicol were in dimethyl sulfoxide (DMSO) at concentrations of 10 mM (luminespib 2 mM). We have ruled out vehicle effects by testing DMSO up to a maximum concentration of 0.1% (not shown).

The human V2-receptor cDNA subcloned in the pEGFP-vector to give a c-terminally appended GFP (green fluorescent protein) was a gift of Dr. Ralf Schülein (Leibniz

### Table 1 Hyponatremia incidence in phase I/II trials of HSP90 inhibitors

| HSP90 inhibitor | Number of events | Number of patients enrolled | Severity grade | References |
|-----------------|-----------------|-----------------------------|----------------|------------|
| 17-DMAG         | 1               | 11                          | 1              | Pacey et al. [3] |
| 17-AAG          | 4               | 25                          | 1, 3           | Pacey et al. [4] |
| 17-AAG (plus docetaxel) | 27           | 49                          | 1, 3           | Iyer et al. [5] |
| 17-AAG (plus bortezomib) | 1           | 11                          | ≥3             | Walker et al. [6] |
| IPI-504         | 2               | 19                          | ≥3             | Oh et al. [7] |
| SNX-5422        | 1               | 33                          | 1              | Rajan et al. [8] |
| Ganetespib      | 3               | 53                          | ≥3             | Goldman et al. [9] |
| Debio0932       | 2               | 80                          | ≥3             | Isambert et al. [10] |
| HSP900         | 2               | 64                          | ≥3             | Spreafico et al. [11] |
| Luminespib (plus erlotinib) | 17           | 37                          | 1, 3           | Johnson et al. [12] |
| Onalespib       | 2               | 31                          | 1, 3           | Do et al. [13] |
| Ganetespib      | 1               | 17                          | 3              | Thakur et al. [14] |
Institute of Molecular Pharmacology, Berlin, Germany). By inserting the receptor cDNA into the pCMV-Tag2B vector (Stratagene, La Jolla, California) a FLAG-epitope sequence was appended to the 5′-end of the V2-receptor coding sequence. The integrity of the construct was verified by fluorescent sequencing.

**Cell culture and transfection**

We used receptor-transfected HEK293 cells propagated in the presence of G418 and stocked in aliquots. Results obtained with this type of culture were indistinguishable from experiments performed after transient transfection (not shown).

HEK293 cells and JEG-3 cells were cultivated in DMEM plus L-glutamine and 10% foetal calf serum. The transfection reagent was JetPEI (Polyplus, Illkirch, France) and was used for transfection with plasmid cDNA and with siRNA oligonucleotides. Culture medium for HELA-S3 cells (HELA) was RPMI 1640 containing foetal calf serum and L-glutamine. JEG-3 cells were used after transient transfection with the receptor expression plasmid.

HELA cells were from the Institute of Cancer Research (Comprehensive Cancer Center Vienna, Medical University of Vienna), JEG-3 cells were a kind gift of Dr. Martin Knöfler (Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna).

Ambion small interfering RNA (siRNAs) directed to human HSP90α (HSP90AA1) and HSP90β (HSP90AB1), consisting of two species of oligonucleotides each, and scrambled-sequence control oligonucleotides were from LifeTechnologies. Routine siRNAs concentrations during transfection were 15 nM. HEK293 cells transfected with siRNAs were subjected to assay 4 days later.

**Determination of surface-receptor density**

HEK293 cells expressing a V2-receptor construct with an N-terminal FLAG-epitope were incubated with HSP90 inhibitors routinely overnight, compounds added to growth medium. After washing with phosphate buffered saline (PBS) cells were detached in EDTA (0.02%) solution. All of the following procedures were performed at 4 °C. Cells were collected by centrifugation and taken up in PBS with 1% BSA in a volume of ~0.3 mL. Cell surface-receptors were labelled with the monoclonal M2 anti-FLAG antibody (at a concentration of ~0.3 µg/100 µL cell suspension) and a secondary anti-mouse IgG conjugated to fluorescent dye (AlexaFluor 488, 0.25 µg/100 µL). Labelling was for a total of 40 min with the primary and for the last 20 min included the secondary antibody. Cells were washed once, resuspended in PBS with 1% BSA and were expedited to measuring cell-bound AlexaFluor 488 fluorescence by flow cytometry.

For flow cytometry, we used a Becton-Dickinson instrument (FacsCanto). Recordings were at 4 °C. For analysis, a cell fraction was gated with forward scatter values higher than 10% of maximum. This fraction was set off from a fraction of non-viable cells stained positive for propidium iodide (not shown). Recording comprised ten thousand events per gate. Receptor-specific fluorescence was determined after excluding events that overlapped the intensity range of non-specific fluorescence (the lower 97% of events recorded on non-transfected HEK293 cells labelled with primary and secondary antibody). The number of events representing the number of cells with the FLAG-tagged receptors on their surface was between 4000 and 8000. Original data are plotted in histograms with the fluorescence intensity on the x-axis and the event count on the y-axis. Overlay histograms were normalized to the peak event count (given as y-axis label).

We quantified treatment-dependent changes by comparing the area under the histogram trace marking the distribution of receptor-specific fluorescence events or used the median value of receptor-specific fluorescence intensity for gauging treatment effects. Analysis of flow cytometry recordings was performed with the use of Flowing Software (Dr. Perttu Terho, Turku Centre for Biotechnology, Finland).

**Visualization of cells expressing GFP-tagged V2-receptor**

HEK293 cells expressing the wild-type receptor fused to GFP were seeded on poly-d-lysine-coated glass bottom dishes. Four days after transfection with siRNA, GFP-fluorescence was recorded with a confocal laser-scanning microscope (Zeiss LSM510). Pinhole was set to limit slice thickness to less than 2.5 µm.

**Determination of cellular cAMP formation**

Formation of cAMP was determined in cells pre-incubated with [3H]adenine. The assay incubations were in Krebs–Henseleit buffer plus an inhibitor of phosphodiesterase (0.1 mM Ro 20-1724) at room temperature, started with the addition of forskolin, the receptor agonist or both as indicated (incubation time was 15 min). Tritiated cAMP was separated chromatographically from radioactive nucleotides and adenine according to [17]. When assays followed a pre-incubation of cells with an HSP90 inhibitor, we allowed the compound to dissociate for a period of 40 min and washed it out before the assay.
Miscellaneous procedures

Binding of [3H]AVP was assayed on a membrane fraction prepared from HEK293 cells transfected with the V2-receptor expression plasmid. Incubation proceeded at room temperature for 90 min in the presence of 50 μg membrane protein according to [18]. Separation of bound and free radioligand was by filtration over glass fibre filters soaked in 0.3% polyethyleneimine. The amount of radioligand bound in the presence of 1 μM SR121463 defined the fraction of non-specific binding; this was ~20% of total binding in the KD concentration range.

Protein concentration in cell fractions was determined with the Bio-Rad Bradford dye.

Statistical analysis was done by repeated-measure ANOVA, which compared treatment-dependent changes within single experiments, or by Kruskal–Wallis ANOVA followed by a post hoc test to compare group means. Where appropriate, we compared means of experimental values between two groups using t test or Mann–Whitney rank-sum tests. Data obtained with graded concentrations of HSP90 inhibitors or AVP were subjected to non-linear curve fitting according to the following equation,

\[ f = y_0 + a x/(b + x), \]

where \( y_0 \) is \( y \) at concentration \( x = 0 \); \( a \) is the maximum effect; \( b \) is the EC50; and \( x \) is the inhibitor concentration. The curve generated by the fitting procedure represents a rectangular hyperbola.

Results

We assessed cell surface expression of the human V2 vasopressin receptor after pre-treatment with the benzoquinone ansamycin DMAG and of two structurally unrelated inhibitors of HSP90, respectively. The number of V2-receptors we determined by radioligand binding and by antibody-labelling of the FLAG-epitope attached to the receptor N-terminus. Figure 1 demonstrates that HSP90 inhibition increased the cell surface density of the V2-receptor. Figure 1a depicts specific binding of [3H]AVP to membranes prepared from HEK293 cells transfected with an expression vector coding for the human V2-receptor. Cell culture was incubated for 20 h with 2 μM DMAG (open symbols in Fig. 1a) or vehicle (0.1% DMSO, closed symbols). In membranes from DMAG-treated cells, the amount of [3H]AVP bound was higher than in membranes from controls; fitting of the data indicated that DMAG incubation increased Bmax estimates by about twofold with no change in affinity for [3H]AVP (controls KD = 1.08 ± 0.65 nM, DMAG-treated = 1.26 ± 0.29 nM, means ± s.d., n = 3).

The relative increase was in the same range when FLAG-tagged receptors were labelled with antibody recognizing the cognate epitope. Antibody-labelling was done on ice, which precluded uptake of primary and secondary antibody. Figure 1b shows original histograms from a set of individual recordings by flow cytometry. The grey trace represents vehicle-treated cells, the black trace cells after pre-incubation with DMAG at the concentrations indicated (0.02, 0.2, 2 μM). The grey-shaded area delimits the fluorescence signal of antibody-labelled untransfected cells (the non-specific signal) and covers ~97% of the events recorded (indicated by the blue trace). It is evident that DMAG shifted the black trace to higher fluorescence values. The area under the trace—reflecting the number of labelled receptors—increased by approximately twofold at the highest DMAG concentration. At higher concentrations of DMAG, there was an additional effect due to enhanced non-specific fluorescence (Fig. 1b). We therefore refrained from escalation of DMAG-concentrations beyond 2 μM and used the median of the fluorescence intensity distribution as a conservative estimate (rather than the area under the trace) for the quantification of differences. Changes in the median of fluorescence intensity are plotted in Fig. 1c. They show that DMAG was effective at submicromolar concentrations after an overnight incubation (EC50 = 0.33 ± 0.24; estimate ± standard error), which is consistent with its affinity for HSP90 [19]. An extended incubation period (16–20 h) was necessary while 2 h produced no effect (data not shown).

In addition to DMAG, we tested radicicol, a cyclic polypeptide and luminespib, a non-cyclic resorcinyl isoxazole amide. Antibody-labelling of the V2-receptor revealed a concentration-dependent increase of surface-receptor density by radicicol and luminespib. A plot of the median values of bound antibody fluorescence is shown in Fig. 1d. Fitting of the data to a rectangular hyperbola gave individual EC50 estimates of 0.08 ± 0.03 and 1.7 ± 0.7 μM for luminespib and radicicol, respectively; the maximum increase was similar to that produced by the highest concentration of DMAG.

Depletion of cytosolic HSP90 increases surface-receptor density

RNA interference (RNAi) confirmed regulation of cell surface receptor density by cytosolic HSP90. We employed four different siRNA oligonucleotides, two directed against each isoform of cytosolic HSP90, HSP90α and HSP90β. Four days after transfecting HEK293 cells with the siRNAs, we recorded confocal images of the GFP-tagged V2-receptor (Fig. 2a) and measured receptor density after antibody-labelling of the FLAG-tagged construct (Fig. 2b). The micrographs shown in Fig. 2a document a change in the subcellular distribution of the GFP-tagged receptor. The fluorescent lines marking cell contours appeared more pronounced in culture transfected with the HSP90-specific siRNAs (HSP90, bottom micrograph in Fig. 2a) than with scrambled-sequence control oligonucleotides (scrambled, top micrograph in Fig. 2a), while the fluorescent signal
Within the cells was reduced. This impression was substantiated by quantification of the fluorescence distribution (not shown). Antibody-labelling of the receptor showed that transfection with HSP90-specific siRNAs augmented V2-receptor density at the cell surface (Fig. 2b, histogram), similar to the effect of HSP90 inhibition. The box
plots summarize three transfection experiments. If cells were transfected with siRNAs targeting both cytosolic isoforms, HSP90 α and β, receptor upregulation was twofold on average and significantly different from control cells transfected with scrambled-sequence control oligonucleotides as indicated. The confocal images (optical slice thickness <2.5 µm) depict the subcellular distribution of the fluorescent receptor. Box plots document the change of receptor fluorescence from three experiments with siRNAs against HSP90α, HSP90β or both (horizontal line = median; borders = 25 and 75% confidence intervals). Statistical comparison was by repeated measures ANOVA; the effect of combined siRNAs was statistically significant versus control (Holm–Sidak test). Western blots show levels of HSP90 in a cytosolic fraction determined after transfection with control (scrambled-sequence oligonucleotides), isoform-specific or with a 1-to-1 combination of α- and β-specific siRNAs. The antibody used to detect HSP90 was directed against both α- and β-isoforms. The blot was probed for GAPDH as loading control. The Western blot shown is representative of two transfection experiments. Effect on receptor surface density was measured by antibody-labeling and flow cytometry; horizontal bars represent means (±s.d.) of the relative change in the medians of fluorescence intensity, which were significantly different between scrambled and HSP90-specific siRNAs (paired t test)
individual isoforms, similarly to the effect on V2-receptor surface density (Fig. 2b, box plots).

Thus, depletion of cytosolic HSP90 mimicked the effect of chemical HSP90 inhibition. With a reduced level of the target, the inhibitor effect is predicted to diminish. In fact, depletion of HSP90 limited the effect of DMAG: receptor upregulation was less relative to controls, which were cells transfected with scrambled-sequence siRNAs. The bars in Fig. 2c document a significant difference of the increments. This finding further substantiates the assumption that receptor upregulation was due to a decline in the activity of cytosolic HSP90.

**Enhanced V2-receptor signalling following HSP90 inhibition**

Receptor upregulation translated into enhanced stimulation of cAMP formation by AVP. This was observed in two cell lines, transfected HEK293 and HELA cells, which express the V2-receptor endogenously. Figure 3a shows that HELA cells responded to nanomolar AVP with an increased formation of cAMP. The effect of AVP was completely suppressed by the addition of the V2-selective antagonist SR121436 (at 100 nM). Pre-incubation with the HSP90-inhibitors DMAG, radicicol and luminespib augmented the V2-receptor response. Figure 3b presents the results of a concentration-dependent stimulation by AVP. It is obvious that HSP90 inhibition enhanced cAMP formation shifting the concentration response curves upward. The effect was most pronounced with DMAG with a nearly twofold sensitization of the response; the AVP-dependent increment over basal was 1.7-fold (±0.4) in controls and threefold (±0.6; s.d. from three experiments) in DMAG-treated culture with no apparent change in agonist potency. Pre-incubation with radicicol (10 μM) and luminespib (0.2 μM) resulted in a somewhat smaller enhancement. We repeated the assays with a stepwise increase of the inhibitor concentration to ascertain that the effect by luminespib and radicicol was compatible with HSP90 inhibition. Figure 3c shows box plots representing cAMP formation at a fixed concentration of AVP. The results demonstrate that for both, radicicol and luminespib, the concentrations were similar to those required for increasing the receptor surface density (cf. Fig. 1d). For the maximal concentrations of each, radicicol and luminespib the pooled data indicate a statistically significant increment relative to the controls, which was comparable in size with the DMAG-effect (~1.3fold).

Figure 3b suggests that HSP90 inhibition also had an effect on the basal rate of cAMP formation (at zero AVP, basal cAMP formation was marginally higher in treated than in untreated culture). Figure 3d shows forskolin-dependent cAMP formation in HELA cells where values were higher in cells pre-incubated with an HSP90 inhibitor. Apparently, the trend was more pronounced after pre-incubation with DMAG (open circle) than with luminespib (open triangle) and radicicol (open square).

Increased basal activity of the catalyst was a cell line-specific effect of HSP90 inhibition, not a generic one. In HEK293 culture, for example, pre-incubation of with HSP90 inhibitors slightly reduced catalyst activity. Figure 4a, b shows that in the presence of forskolin at higher concentrations, cAMP formation was somewhat lower than in the controls. An appreciable reason is reduced viability of the HEK293 culture on HSP90 inhibition (HELA cells in contrast appeared resistant to a detrimental effect).

Because we could not be certain of the fraction of cell culture contributing to cAMP formation, we normalized AVP-stimulated Camp formation to basal values; to elevate basal values, we assayed cAMP formation also in the presence of forskolin only (10 μM). Figure 4c documents AVP-stimulated cAMP production in transfected HEK293 cells after DMAG treatment; that is the ratio of AVP values over forskolin values, relative to vehicle-treated cells. The box plots in Fig. 4d show the ratios after pre-incubation with radicicol and luminespib. For each inhibitor the increase was statistically significant and consistent with the greater number of surface V2-receptors after inhibition of HSP90.

**Discussion**

Preclinical drug profiling allows for predicting a range of side effects, but there is a limit to the number of targets against which drug candidates can be screened. Thus, phase I/II trials may reveal unanticipated toxicities. Adverse effects that become dose-limiting are of particular concern in the treatment of cancer. Nevertheless, deciphering the mechanistic basis of an adverse effect is an opportunity to uncover important regulations not appreciated previously. HSP90 inhibitors represent a novel treatment modality aimed at tumours with cells relying on HSP90 activity. Hyponatremia is a surprising side effect for patients exposed to an HSP90 inhibitor. The prime, if not sole, plausible candidate for a mechanistic explanation is vasopressin or vasopressin-dependent signalling. Vasopressin by activating the renal V2-receptor controls the concentration of sodium in the extracellular space. Here we investigated the mechanistic basis of hyponatremia by exploring the possibility that HSP90 inhibition enhanced signalling via the V2-receptor. Our experiments unequivocally demonstrated that HSP90 inhibitors increase the sensitivity of cells to vasopressin by raising V2-receptor levels based on the following observations. (1) Incubation of cells with an HSP90 inhibitor resulted in upregulation of the V2-receptor. Antibody-labelling of the receptor and binding of [3H]AVP indicated consistently that the increment was about twofold. The effect
was seen with three inhibitor compounds, which differed in structure and affinity. (2) The upregulated receptors were fully functional; the increased surface density translated into commensurately enhanced receptor-mediated cAMP formation. (3) Enhanced V2-receptor signalling was independent of the cell type employed and was seen regardless of whether receptor expression was driven form the endogenous promoter in HELA cells or from the viral promoter provided by the plasmid used for heterologous expression of the receptor. (4) Depletion of HSP90 by siRNA-mediated downregulation recapitulated the effect of HSP90 inhibitors on V2-receptor levels.

The increased surface-receptor density and enhanced receptor-mediated cAMP formation is the plausible
mechanism underlying the development of hyponatremia. Previously, Caltabiano and Kinter reported an experiment in normal rats chronically infused with a V2-receptor antagonist; the treatment led to upregulation of renal V2-receptors with significantly lower urine volume and increased urine osmolality [20]. Similarly in patients with nephrogenic diabetes insipidus (NDI), V2-receptor upregulation led to less voluminous, more concentrated urine [21]. Both of these observations underpin the consequence of an increased V2-receptor density for water re-absorption. Relative to the situation in patients administered an HSP90 inhibitor, the finding from the animal experiment probably is more relevant than are the results from patients treated for NDI. In the latter case receptor levels are below a certain threshold limit where modest upregulation suffices to generate a V2-receptor signal quantum and restore vasopressin responsiveness [21].

Based on the pertinent evidence it is safe to say that V2-receptor stimulated cAMP formation represents the appropriate surrogate parameter to predict increased renal water re-absorption. Cyclic AMP formation is the first signalling step in recruiting aquaporin 2 to the apical membrane patch of renal duct epithelia (reviewed in [22]). Cyclic AMP activates protein kinase A to phosphorylate aquaporin 2 (on serine residue 256), which initiates appropriate positioning of the water channel. Since cAMP is the relevant second messenger, prostaglandin E2 stimulates antidiuresis via Gs-coupled EP4 receptors present on collecting duct epithelial cells. Prostaglandin E2 regulates cAMP formation and urine concentration but it does not supplant the dominant role of vasopressin [23].

Our finding in cell culture that HSP90 inhibition increased the number of functional V2-receptors supports a cause-and-effect relationship.

We rule out that V2-receptor upregulation by HSP90 inhibitors results from an off-target effect. First, depletion of cytosolic HSP90, of both isoforms α and β, reproduced the effect of the inhibitors. With partial HSP90 depletion, the inhibitor effect diminished proportionally. Secondly, the effect sizes were in the same range with each HSP90 inhibitor if estimated from the increment in receptor density or receptor-mediated cAMP formation. Third, the concentration-dependence of receptor upregulation reflected the inhibitory potencies of the three chemically unrelated HSP90 ligands. Our data indicated EC50 values in the nanomolar, the submicromolar and micromolar concentration range for luminespib, DMAG and radicicol, respectively. These estimates are in agreement with values published in the literature [19, 24]. For radicicol, the potency varies with the cell type used to gauge the effect of HSP90 inhibition and is deemed lower in HEK293 culture than in others [16, 25, 26]. The model cells we have used were either resistant (HELA) or moderately susceptible (HEK293) to the cytotoxic effect of HSP90 inhibition. In our hands, choriocarcinoma cells (JEG-3 cell line) were affected the most and significant fractions of the culture were lost following incubation with HSP90 inhibitor. Similar to the HEK293 culture, however, a cAMP assay suggested that the heterologous V2-receptor was more active in treated than in untreated JEG-3 cells.

Fig. 4 Signalling by the V2-receptor heterologously expressed in HEK293-cells after pre-incubation with HSP90 inhibitors. a, b Formation of cAMP at various concentrations of forskolin in transfected HEK293 cells pre-incubated in a with vehicle (filled circle) or DMAG (2 µM, o) and in d with vehicle (filled circle), luminespib (0.2 µM, open triangle) or radicicol (10 µM, filled square). Data represent means from two experiments performed in triplicates (±s.e.m.). c HEK293 cells transfected with the V2-receptor and treated overnight with DMAG or vehicle were assayed for cAMP on stimulation with AVP (10 nM) and separately, with forskolin (10 µM). The cAMP values obtained with AVP were normalized to those obtained with forskolin (values amounting to between 3000 and 5000 cpm/well) in the same experiment. Box plots depict the average of three experiments in quadruplicate determinations (borders representing the 75th and 25th percentiles, whiskers the 90th and 10th percentiles). The difference between control and DMAG-pre-treated cells was confirmed by Mann–Whitney statistics (p < 0.05).

d Cells treated with radicicol (10 µM), luminespib (0.2 µM) or vehicle (untreated) were assayed for cAMP formation. Similar to c AVP-mediated cAMP formation is given relative to the cAMP formed in the presence of forskolin in the same experiment (n = 4). Repeated measures ANOVA indicated a significant difference (p < 0.05).
(data not shown). Thus, receptor upregulation was unrelated to cytotoxicity in cells treated with an HSP90 inhibitor.

Cytosolic HSP90 acts as molecular chaperone and assists the folding of client proteins. Many protein kinases and transcription factors depend on an association with HSP90 for their activity and stability. HSP90 can also control the level of transmembrane proteins at the cell surface: this has been demonstrated for G-protein-coupled receptors, e.g. the α2C-adrenergic receptor [15] and the A2A adenosine receptor [16] and for transporters, e.g. the renal Na+/Cl−-symporter/SLC12A1 [27] and the serotonin transporter/SLC6A4 [28]. In those instances, where the mechanistic details were examined, HSP90 was found to act in a relay with other heat-shock proteins at the level of the endoplasmic reticulum [16, 27, 28].

Along their biosynthetic pathway, G-protein-coupled receptors (GPCRs) are subject to a stringent quality control [29]. Inhibition of HSP90 can relax quality control, which may translate into increased export of GPCRs from the endoplasmic reticulum and hence augment receptor levels at the cell surface [15, 16]. It is not clear, however, whether this is the case with the V2 vasopressin receptor. There is also precedent for an action of HSP90 on later steps in GPCR trafficking [30]. Regardless of the underlying mechanism, our observations provide evidence that receptor upregulation causes hypersensitivity to vasopressin. For water retention to occur, an additional stimulus must shortcut feedback regulation to prevent a decline of the hormone. Consequently, activation of the V2-receptors present at increased density will raise cAMP to a level incommensurate with the physiological requirement.

The vasopressin feed back loop likely accounts for the observation that many more patients treated with an HSP90 inhibitor in clinical trials were unaffected than affected by hyponatremia. In patients with no evidence of hyponatremia, secretion of vasopressin presumably adjusted to the excessive sensitivity of renal V2-receptor signalling. In affected patients, however, an additional trigger must uphold hormone secretion to cause water retention. For example, a fall in blood pressure may act as a trigger; low blood pressure can powerfully increase vasopressin secretion despite normal serum osmolality.

Table 1 also includes two trials where the hyponatremia incidence rate was exceptionally high amounting to about 50% of the number of patients enrolled [5, 12]. In these trials, the HSP90 inhibitor was applied in combination with another anti-tumour drug—either erlotinib or docetaxel. The drug combination apparently enhanced the interpretation that—by upregulating the V2-receptor and initiating aquaporin 2 translocation—the EGF-receptor inhibitor erlotinib in combination with an HSP90 inhibitor maximized susceptibility to vasopressin. In this situation, vasopressin should be effective even at rather low levels.

If hypersensitivity to vasopressin is considered causal, vasopressin receptor antagonists appear a logical treatment option. Current guidelines however advise against the use of V2-receptor antagonists in patients with acute hyponatremia presumably including those treated for cancer [32]. Another reason for caution is that experiments on select tumour cell lines have suggested an inhibitory effect of the hormone. Recently for example, Pifano et al. [33] reported on an anti-proliferative effect mediated by the V2-receptor in a tumour cell xenograft model. Such observations would argue against the use of a V2-receptor antagonist in cancer patients; yet there is no evidence in the literature that treatment with an antagonist promotes growth or spread of cancer.

As per the original concept, HSP90 makes for an exquisite target in tumour cells addicted to HSP90, which implies that an inhibitor should effectively suppress tumour growth at submaximal concentrations. A conclusion from our data—in conjunction with the results from clinical trials—is that maximal concentrations give rise to unexpected adverse effects because they may interfere with many a function cytosolic HSP90 has in cell biology.

Acknowledgements Open access funding provided by Medical University of Vienna. The authors thank Drs. Ralf Schülein and Klaudia Rutz for sharing the human V2-receptor cDNA and Dr. Edin Ibrisimovic for assistance in the generation of transfection vectors.

Compliance with ethical standards

Conflict of interest Qiong Yang declares that she has no conflict of interest. Florian Puhm declares that he has no conflict of interest. Michael Freissmuth declares that he has no conflict of interest. Christian Nanoff declares that he has no conflict of interest.

Human and animals rights statement This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Uehara Y, Murakami Y, Mizuno S, Kawai S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbinycin A. Virology 164:294–298
2. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 18:64–76
3. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetland A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Ronso JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17:1561–1570
4. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker K, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T (2012) A Phase II trial of 17-allylamo, 17-deoxymethylgeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 30:341–349
5. Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steens M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB (2012) A phase I trial of docetaxel and pulse-dose 17-allylamo-17-deoxymethylgeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 69:1089–1097
6. Walker AR, Klisovic R, Johnston JS, Yi, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W (2013) Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allylamo-17-deoxymethylgeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 54:1996–2002
7. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IP1-504), in patients with castration-resistant prostate cancer. Urology 78:626–630
8. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon MM, Kummara S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17:6831–6839
9. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofiliivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Goo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. doi:10.1186/1471240713152
10. Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rousi E, Belleri R, Fumoleau P (2015) Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncol 26:1005–1011
11. Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siau LL, Cortes J (2015) A first-in-human phase I, dose-escalation, multicentre study of HSP900 administered orally in adult patients with advanced solid malignancies. Br J Cancer 112:650–659
12. Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ (2015) Phase I/II Study of HSP90 inhibitor AUY922 and erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 33:1666–1673
13. Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummer S (2015) Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalesipib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs 33:921–930
14. Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dziczik SH, Li X, Freeman S, Smith D, Heath EI (2016) A Phase II trial of ganetespib, a heat shock protein 90 Hsp90 inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCCT) study. Invest New Drugs 34:112–118
15. Filipeanu CM, de Vries R, Danser AH, Kapusta DR (2011) Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90. Biochim Biophys Acta 1813:346–357
16. Bergmayer C, Thurner P, Keuerleber S, Kudlacek O, Nonhoff C, Freissmuth M, Gruber CW (2013) Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. J Biol Chem 288:28831–28844
17. Johnson R, Alvarez R, Salomon Y (1994) Determination of adenyl cyclase catalytic activity by use of single and double column procedures. Methods Enzymol 238:31–56
18. Marchingo AJ, Abrahams JM, Woodcock EA, Smith AI, Mendelsohn FA, Johnston CI (1988) Properties of [3H]-desamino-8-d-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney. Endocrinology 122:1328–1336
19. Onoua SC, Mukund SR, Coulstock ET, Sengerová B, Shaw J, McLaughlin SH, Jackson SE (2007) Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 372:287–297
20. Caltabiano S, Kinter LB (1991) Ureaplanation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats. J Pharmacol Exp Ther 258:1046–1056
21. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Lapierrière A, Brouard R, Bouvier M, Bichet DG (2006) Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17:232–243
22. Vukčević T, Schulz M, Faust D, Klussmann E (2016) The trafficking of the water channel aquaporin-2 in renal principal cells—a potential target for pharmacological intervention in cardiovascular diseases. Front Pharmacol 7:23
23. Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson JÅ, Guan Y (2015) Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc Natl Acad Sci USA 112:8397–8402
24. Eccles SA, Massey A, Raynaud FI et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850–2860
25. Hosoi T, Kohda T, Matsuoka S, Ishiguchi M, Kuwamura A, Akita T, Tanaka J, Ozawa K (2016) Key role if heat shock protein 90 (HSP90) for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 68:2850–2860
26. Roe SM, Prodromou C, O’Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone relay by the A2A adenosine receptor. J Biol Chem 288:28831–28844
chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260–266
27. Donnelly BF, Needham PG, Snyder AC, Roy A, Khadem S, Brodsky JL, Subramanya AR (2013) Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis. J Biol Chem 288:13124–13135
28. El-Kasaby A, Koban F, Sitte HH, Freissmuth M, Sucic S (2014) A cytosolic relay of heat shock proteins HSP70-1A and HSP90β monitors the folding trajectory of the serotonin transporter. J Biol Chem 289:28987–29000
29. Nanoff C, Freissmuth M (2012) ER-bound steps in the biosynthesis of G protein-coupled receptors. Subcell Biochem 63:1–21
30. He F, Qiao ZH, Cai J, Pierce W, He DC, Song ZH (2007) Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration and signaling of a G protein-coupled receptor. Mol Pharmacol 72:1289–1300
31. Cheung PW, Nomura N, Nair AV, Pathomthongtaweewchai N, Ueberdiek L, Lu HA, Brown D, Bouley R (2016) EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption. J Am Soc Nephrol 27:3105–3116
32. Hoorn EJ, Zietse R (2017) Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol 28:1340–1349
33. Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF, Ripoll GV (2017) Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells. Front Oncol 7:11